Myelodysplasia
Information
- Disease name
- Myelodysplasia
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03431090 | Active, not recruiting | Phase 1/Phase 2 | Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia | March 2, 2018 | December 2024 |
| NCT03674411 | Active, not recruiting | Phase 2 | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | January 2, 2019 | June 28, 2024 |
| NCT04173533 | Active, not recruiting | Phase 3 | Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT | June 14, 2019 | April 2025 |
| NCT02338479 | Active, not recruiting | Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies | March 2015 | December 2023 | |
| NCT03480360 | Active, not recruiting | Phase 3 | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | March 28, 2018 | September 13, 2025 |
| NCT00899223 | Active, not recruiting | Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes | May 1996 | ||
| NCT00511537 | Completed | Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders | January 1999 | June 2009 | |
| NCT00513175 | Completed | Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia | October 2001 | November 2007 | |
| NCT00516152 | Completed | Phase 2 | Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT | November 2002 | November 2007 |
| NCT00578942 | Completed | Phase 2 | Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath | May 2005 | April 2013 |
| NCT00580242 | Completed | Phase 1 | A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia | November 2007 | March 2012 |
| NCT00580034 | Completed | Phase 2 | Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath | February 2003 | April 2013 |
| NCT00136422 | Completed | Phase 1 | Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia | January 2000 | March 2006 |
| NCT00145626 | Completed | Phase 2 | HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies | May 2004 | July 2016 |
| NCT00195533 | Completed | Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients | July 2001 | March 2005 | |
| NCT00354120 | Completed | Phase 2/Phase 3 | Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant | March 2005 | August 2011 |
| NCT00506402 | Completed | Phase 1 | A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies | November 2006 | April 2009 |
| NCT00597714 | Completed | Phase 2 | Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant | February 2008 | November 2013 |
| NCT00606437 | Completed | Phase 1 | Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants | September 2005 | February 2014 |
| NCT00795132 | Completed | Phase 2 | Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies | April 2004 | July 2009 |
| NCT00862719 | Completed | Phase 2 | Sitagliptin Umbilical Cord Blood Transplant Study | March 2009 | February 2015 |
| NCT00975975 | Completed | Phase 2 | Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer | September 2009 | November 2013 |
| NCT00990587 | Completed | Phase 1 | Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | October 2009 | |
| NCT01095874 | Completed | Allogeneic Hematopoietic Stem Cell Transplantation Evaluation in High Risk Myelodysplasia: an Observational Non-interventional Study | January 2008 | ||
| NCT01110473 | Completed | Phase 1 | ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies | April 2010 | June 2013 |
| NCT01297543 | Completed | Phase 1/Phase 2 | Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia | March 2011 | January 2015 |
| NCT01422603 | Completed | Phase 1/Phase 2 | Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) | February 2011 | March 31, 2015 |
| NCT01904175 | Completed | Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant | August 2013 | April 2016 | |
| NCT01911871 | Completed | Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations | March 2012 | March 2015 | |
| NCT01933035 | Completed | Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias. | October 2013 | October 2015 | |
| NCT01956799 | Completed | Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy | May 2013 | December 2019 | |
| NCT02007863 | Completed | N/A | Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia | August 2008 | June 2014 |
| NCT02208037 | Completed | Phase 2 | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | August 2014 | October 2017 |
| NCT02345850 | Completed | Phase 3 | Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301) | August 2015 | October 5, 2020 |
| NCT03613727 | Completed | Phase 2 | Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients | October 1, 2018 | October 6, 2022 |
| NCT03959241 | Completed | Phase 3 | TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801) | June 25, 2019 | September 19, 2022 |
| NCT05260203 | Completed | N/A | MargheRITA (Remote Intelligence for Therapeutic Adherence) | June 4, 2022 | January 16, 2023 |
| NCT05154474 | Not yet recruiting | Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy | June 2022 | August 2024 | |
| NCT02323867 | Recruiting | Phase 2 | Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies | October 2014 | October 2026 |
| NCT04800458 | Recruiting | N/A | Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis | May 19, 2021 | May 2027 |
| NCT03314974 | Recruiting | Phase 2 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | March 30, 2018 | November 10, 2025 |
| NCT03387475 | Recruiting | Phase 2 | Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents | February 20, 2018 | December 31, 2024 |
| NCT05794880 | Recruiting | N/A | MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing | May 1, 2023 | May 2032 |
| NCT05735717 | Recruiting | Phase 2 | MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | May 11, 2023 | November 30, 2030 |
| NCT04202835 | Recruiting | Phase 2 | ATG Plus PTCy vs ATG for CGVHD Prophylaxis | October 13, 2020 | December 31, 2024 |
| NCT01962636 | Recruiting | N/A | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases | December 2016 | October 2025 |
| NCT00963495 | Terminated | Phase 1 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy | August 2009 | September 2013 |
| NCT04166929 | Terminated | Phase 2 | Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS | January 15, 2020 | September 28, 2023 |
| NCT00514722 | Terminated | N/A | Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies | October 2002 | March 2009 |
| NCT00513318 | Terminated | Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies | August 2004 | June 2009 | |
| NCT00212407 | Terminated | Early Phase 1 | New York Blood Center National Cord Blood Program | February 1993 | November 10, 2011 |
| NCT00593554 | Terminated | Phase 2 | Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies | August 7, 2007 | July 28, 2017 |
| NCT00594308 | Terminated | N/A | In-Vivo Activated T-Cell Depletion to Prevent GVHD | October 2007 | |
| NCT00109538 | Terminated | Phase 3 | Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) | May 2005 | August 2008 |
| NCT00740181 | Terminated | Phase 2 | Decitabine, Cytarabine, GCSF for Refractory AML/MDS | August 2008 | April 2010 |
| NCT05223699 | Terminated | Phase 1 | Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB) | February 14, 2022 | February 2, 2023 |
| NCT00434239 | Unknown status | Early Phase 1 | Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of Myelodysplasia | February 2007 | May 2014 |
| NCT02765997 | Withdrawn | Phase 2 | StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies | April 2017 | June 2022 |
- HPO alt_id (Human Phenotype Ontology)
- HP:0004832
- HPO alt_id (Human Phenotype Ontology)
- HP:0006730
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0002863